Pre-treatment CXCL13+ tumor-reactive T cells were associated with a favorable response to ICIs in TNBC, and were significantly expanded after treatment with chemotherapy combined with ICIs (Zhang et al., 2021; Liu et al., 2022). This evidence concerns the gene CXCL13 and neoplasm.